This was consistent with findings after GLP-1 antagonist administration, which resulted in larger activations indicating that GLP-1 antagonists may reduce modulatory effects of RYGB in participants with obesity (ten Kulve et al., 2017)
Who Is a Candidate for TB-500 at Perfect B
Dickenson AH, Sullivan AF
Co ciekawe, cz z prezentowanych w artykule lekw inkretynowych zatwierdzonych jest przez Europejsk Agencj Lekw rwnie do leczenia otyoci bez wsptowarzyszcego zaburzenia kontroli stenia glukozy we krwi
The pivotal trial programs are STEP (semaglutide for weight management, The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
These precise targeting strategies can effectively reduce off-target effects and hold the potential for achieving precise redox regulation